StreetInsider.com News Articles

Acumen Pharmaceuticals beats Q3 estimates, shares jump 6%

Mon, 26 Oct 2026 07:57:46 -0400

Investing.com -- On Monday, Acumen Pharmaceuticals Inc. (NASDAQ:ABOS) reported third quarter results that exceeded analyst expectations.

The clinical-stage biophharma company’s shares went up 5.56% in pre-market trading following the announcement.

The company posted an adjusted loss per share of -$0.35 for the third quarter, beating the analyst consensus estimate of -$0.38 by $0.03. The company reported a net loss of $25.4 million for the quarter ended September 30, 2026, compared to a net loss of $26.5 million in the same period last year.

"In the third quarter, we continued readying for the readout from our ALTITUDE-AD Phase 2 study investigating

Acumen Pharmaceuticals beats Q3 estimates, shares jump 6%

Mon, 26 Oct 2026 07:57:46 -0400

Investing.com -- On Monday, Acumen Pharmaceuticals Inc. (NASDAQ:ABOS) reported third quarter results that exceeded analyst expectations.

The clinical-stage biophharma company’s shares went up 5.56% in pre-market trading following the announcement.

"In the third quarter, we continued readying for the readout from our ALTITUDE-AD Phase 2 study investigating

Acumen Pharmaceuticals, Inc. (ABOS) Tops Q3 EPS by 3c

Mon, 26 Oct 2026 07:31:45 -0400

Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) reported Q3 EPS of ($0.35), $0.03 better than the analyst estimate of ($0.38).

For earnings history and earnings-related data on Acumen Pharmaceuticals, Inc. (ABOS) click here.

Form 8-K Acumen Pharmaceuticals, For: Oct 26

Mon, 26 Oct 2026 07:09:00 -0400

si-local-file:///var/storage/secattach/20261026/27230548.html

Acumen Pharmaceuticals Reports Third Quarter 2026 Financial Results and Business Highlights

Mon, 26 Oct 2026 07:00:00 -0400

Expect to report topline results for ALTITUDE-AD, a Phase 2 study to investigate sabirnetug (ACU193) for the treatment of early Alzheimer’s disease, in November 2026
IND filing for the Enhanced Brain Delivery™ (EBD^®) program lead clinical candidate targeted for mid-2027
Cash, cash equivalents and marketable securities of $78.6 million as of September 30, 2026, expected to support current clinical and operational activities into early 2027
Company to host conference call and webcast today at 8:00 a.m. ET

NEWTON, Mass., Oct. 26, 2026 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a

Acumen Pharmaceuticals Reports Third Quarter 2026 Financial Results and Business Highlights

Mon, 26 Oct 2026 07:00:00 -0400

Expect to report topline results for ALTITUDE-AD, a Phase 2 study to investigate sabirnetug (ACU193) for the treatment of early Alzheimer’s disease, in November 2026
IND filing for the Enhanced Brain Delivery™ (EBD^®) program lead clinical candidate targeted for mid-2027
Cash, cash equivalents and marketable securities of $78.6 million as of September 30, 2026, expected to support current clinical and operational activities into early 2027
Company to host conference call and webcast today at 8:00 a.m. ET

NEWTON, Mass., Oct. 26, 2026 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a

Acumen Pharmaceuticals to present Phase 2 trial data at CTAD

Thu, 22 Oct 2026 07:30:12 -0400

Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) will present three poster presentations at the 19th Annual Clinical Trials on Alzheimer's Disease (CTAD) conference in Boston, scheduled for November 16-19, 2026, according to a company statement.

The presentations will cover data from Acumen's Phase 2 ALTITUDE-AD trial of sabirnetug (ACU193), an investigational treatment for early Alzheimer's disease. The three posters will address preliminary baseline characteristics of trial participants, qualitative interviews on treatment expectations and motivations for participation, and care partner perspectives on the experience of living with early Alzheimer's disease.

All three presentations are scheduled as part of Poster Session 1, running from Monday, November

Acumen Pharmaceuticals to Present Preliminary Baseline Characteristics and Data on Care Experiences and Participation in Phase 2 ALTITUDE-AD Trial at the 19th Annual Clinical Trials on Alzheimer’s D

Thu, 22 Oct 2026 07:30:00 -0400

NEWTON, Mass., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (Acumen), a clinical-stage biopharmaceutical company developing novel therapeutics that target soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer’s disease (AD), will present three key poster presentations at the upcoming 19^th Annual Clinical Trials on Alzheimer’s Disease (CTAD) conference taking place in Boston. The presentations focus on Acumen’s Phase 2 ALTITUDE-AD trial of sabirnetug (ACU193) for the treatment of early AD, including preliminary baseline characteristics of study participants, study participant and partner experience, and treatment expectations and motivations. The conference will be held

Acumen Pharmaceuticals to Present Preliminary Baseline Characteristics and Data on Care Experiences and Participation in Phase 2 ALTITUDE-AD Trial at the 19th Annual Clinical Trials on Alzheimer’s D

Thu, 22 Oct 2026 07:30:00 -0400

Acumen Pharmaceuticals to Report Third Quarter Financial Results on October 26, 2026

Mon, 19 Oct 2026 16:00:00 -0400

NEWTON, Mass., Oct. 19, 2026 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics that target toxic soluble amyloid beta oligomers for the treatment of Alzheimer’s disease, today announced that the Company will report third quarter financial results on Monday, Oct. 26, 2026. The Company will host a conference call and live audio webcast at 8:00 a.m. ET to provide a business and financial update.

To participate in the live conference call, please register using this link. After registration, you will be informed

Acumen Pharmaceuticals to Report Third Quarter Financial Results on October 26, 2026

Mon, 19 Oct 2026 16:00:00 -0400

To participate in the live conference call, please register using this link. After registration, you will be informed

U.S. biotech SMids: Q3 earnings preview

Sun, 18 Oct 2026 20:00:00 -0400

Citi is out with its preview into Q3 earnings of U.S. Smid biotech stocks, noting that a continued catalyst calendar and business development engagement have kept investor interest high in this part of the market. The firm has shared with investors key catalysts to watch.

While conversations on large-cap Biopharma tend to have policy and AI in focus, SMids “offer a more direct investment case around clinical data, regulatory progress, and launch execution.”